JVI Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by De, S. K.
Right arrow Articles by Notkins, A. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De, S. K.
Right arrow Articles by Notkins, A. L.

 Previous Article  |  Next Article 

Journal of Virology, November 2002, p. 11710-11714, Vol. 76, No. 22
0022-538X/02/$04.00+0     DOI: 10.1128/JVI.76.22.11710-11714.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Elevated Levels of Tumor Necrosis Factor Alpha (TNF-{alpha}) in Human Immunodeficiency Virus Type 1-Transgenic Mice: Prevention of Death by Antibody to TNF-{alpha}

Swapan K. De,{dagger} Krishnakumar Devadas, and Abner Louis Notkins*

Experimental Medicine Section, Oral Infection and Immunity Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland 20892

Received 27 March 2002/ Accepted 1 August 2002

Homozygous human immunodeficiency virus type 1 (HIV-1)-transgenic mice (Tg26) appear normal at birth but die within 3 to 4 weeks. The skin of these animals shows diffuse scaling and high-level expression of both HIV-1 mRNA and gp120. Previous experiments showed that treatment with human chorionic gonadatropin (hCG) prevented death and the expression of HIV-1 mRNA and gp120. The present experiments were initiated to study the role of tumor necrosis factor alpha (TNF-{alpha}) in HIV-1-induced pathology. Examination of the sera of Tg26 mice revealed a 50-fold increase in TNF-{alpha} levels compared to those in nontransgenic mice. Treatment with antibody to TNF-{alpha} prevented death, resulted in near normal growth, and produced a marked decrease in skin lesions and a profound reduction in the expression of HIV-1 mRNA and gp120. Both TNF-{alpha} antibody and hCG reduced TNF-{alpha} levels in sera by approximately 75%. We conclude that TNF-{alpha} contributes in a major way to HIV-1-induced pathology in transgenic mice and that both hCG and antibody to TNF-{alpha} prevent the development of pathology by suppressing the level of TNF-{alpha}.

* Corresponding author. Mailing address: Experimental Medicine Section, Oral Immunity and Infection Branch, Building 30, Room 121, NIDCR, National Institutes of Health, 30 Convent Dr., MSC 4322, Bethesda, MD 20892-4322. Phone: (301) 496-4535. Fax: (301) 402-4163. E-mail: anotkins{at}dir.nidcr.nih.gov.

{dagger} Present address: Center for Drugs Evaluation and Research, Food and Drug Administration, Rockville, MD 20857-0001.

Journal of Virology, November 2002, p. 11710-11714, Vol. 76, No. 22
0022-538X/02/$04.00+0     DOI: 10.1128/JVI.76.22.11710-11714.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. Mol. Cell. Biol. Microbiol. Mol. Biol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2002 by the American Society for Microbiology. All rights reserved.